Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis in HIV/AIDS Patients in India-A Pilot Pharmacokinetic Study.
The liposomal formulation of amphotericin B greatly reduces side effects like nephrotoxicity. The present pilot study describes the pharmacokinetic characteristics of liposomal Amp B given to eight patients of cryptococcal meningitis with HIV/AIDS at a dose of 1 and 3 mg/kg/day. We observed that the pharmacokinetic parameters namely AUC, Cmax , CL, Vd, and half-life were not proportionate with 1 and 3 mg/kg/day dose of Fungiosme™. With 1 and 3 mg/kg/day dose the mean Cmax was found to be 626.54 ± 39.26 and 1049.90 ± 742.75 ng/mL, respectively. In conclusion, liposomal Amp B was observed to be safe and efficacious in the treatment of cryptococcal meningitis in HIV/AIDS patients, however, a pharmacokinetics study with larger cohort of patients of cryptococcal meningitis in HIV AIDS is warranted.
Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Manoj
M
Jadhav
Department of Infectious Diseases, MUHS, Seth G.S. Medical College and KEM Hospital, Parel, Mumbai, India.
Priyanka
P
Jadhav
Department of Clinical Pharmacology, Seth G.S. Medical College and KEM Hospital, Parel, Mumbai, India.
Vishal
V
Shinde
Department of Clinical Pharmacology, Seth G.S. Medical College and KEM Hospital, Parel, Mumbai, India.
Prashant
P
Kadam
National Chair, Clinical Pharmacology, Indian Council for Medical Research (New Delhi), MGM, Hospital, Parel, Mumbai, India.
Nilima
N
Kshirsagar
amphotericin B; cryptococcal meningitis; liposomes; pharmacokinetics; systemic fungal infections